ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,288Medicare Part D Prescriptions Filled, Including Refills

Rank: 28 out of 978

$530K Total Retail Price of All Prescriptions

Rank: 41 out of 978

484 Patients Receiving at Least One Drug in Part D
74%Patients 65 Years and Older
74% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Massachusetts
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 484 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

5% of this provider’s 484 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 7,334 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$52 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Massachusetts
WARFARIN SODIUM 490 454 1 11
LISINOPRIL 463 335 2 1
LEVOTHYROXINE SODIUM 443 292 3 4
OMEPRAZOLE 342 159 4 3
SIMVASTATIN 338 235 5 2
AMLODIPINE BESYLATE 299 256 6 6
FUROSEMIDE 297 245 7 9
METFORMIN HCL 251 144 8 7
CITALOPRAM HBR 249 220 9 14
ATENOLOL 241 222 10 8
TRAZODONE HCL 230 195 11 18
METOPROLOL TARTRATE 211 180 12 10
MIRTAZAPINE 197 182 13 31
GABAPENTIN 169 119 14 15
DONEPEZIL HCL 164 164 15 26
SERTRALINE HCL 119 103 16 21
POTASSIUM CHLORIDE 112 87 17 41
HYDROCHLOROTHIAZIDE 110 88 18 5
PREDNISONE 108 80 19 47
POLYETHYLENE GLYCOL 3350 98 28 20 58
ALENDRONATE SODIUM 94 58 21 20
SPIRIVA 91 59 22 37
RISPERIDONE 91 67 22 49
QUETIAPINE FUMARATE 90 75 24 51
ADVAIR DISKUS 83 44 25 35
FLUTICASONE PROPIONATE 82 29 26 28
METOPROLOL SUCCINATE 81 77 27 13
NAMENDA 71 71 28 45
HYDROCODONE-ACETAMINOPHEN 70 33 S3 29 17
RANITIDINE HCL 70 40 29 27
DIGOXIN 69 58 31 54
AZITHROMYCIN 69 58 31 68
ATORVASTATIN CALCIUM 68 38 33 12
FINASTERIDE 67 67 34 72
LOSARTAN POTASSIUM 65 65 35 22
TAMIFLU 62 53 36 246
SPIRONOLACTONE 62 56 36 87
NYSTOP 59 55 38 118
TERAZOSIN HCL 58 34 39 76
CRESTOR 58 29 39 30
ALLOPURINOL 57 56 41 34
LISINOPRIL-HYDROCHLOROTHIAZIDE 57 33 41 36
METHADONE HCL 56 0 S2 43 107
PROAIR HFA 54 21 44 19
LANTUS 53 38 45 40
TAMSULOSIN HCL 52 40 46 33
TRAMADOL HCL 51 50 47 24
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 27, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.